Drugs / GS-0201
last change Jan 2024 re-read 2 minutes ago

GS-0201

Developed for
cancer
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

20242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06167317 Jan 2024 → Sep 2028 expected cancer Gilead Sciences Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GS-0201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06167317
Route Oral “Pill administered orally” NCT06167317